219 related articles for article (PubMed ID: 32124692)
1. Clinical Application of Thiopurine Pharmacogenomics in Pediatrics.
Pavlovic S; Kotur N; Stankovic B; Gasic V; Lucafo M; Decorti G; Zukic B
Curr Drug Metab; 2020; 21(1):53-62. PubMed ID: 32124692
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacogenomics of thiopurine S-methyltransferase.
Zhou S
Curr Clin Pharmacol; 2006 Jan; 1(1):119-28. PubMed ID: 18666383
[TBL] [Abstract][Full Text] [Related]
3. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
4. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Gutiérrez-Valencia M; Leache L; Saiz LC; Beloqui JJ; Barajas M; Vicuña M; Erviti J
J Clin Gastroenterol; 2023 Aug; 57(7):671-685. PubMed ID: 36322453
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
6. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
8. A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.
Skrzypczak-Zielinska M; Borun P; Bartkowiak-Kaczmarek A; Zakerska-Banaszak O; Walczak M; Dobrowolska A; Kurzawski M; Waszak M; Lipinski D; Plawski A; Slomski R
Mol Diagn Ther; 2016 Oct; 20(5):493-9. PubMed ID: 27307154
[TBL] [Abstract][Full Text] [Related]
9. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics and ALL treatment: How to optimize therapy.
Karol SE; Yang JJ
Semin Hematol; 2020 Jul; 57(3):130-136. PubMed ID: 33256902
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics in inflammatory bowel disease.
Egan LJ; Derijks LJ; Hommes DW
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):21-8. PubMed ID: 16431300
[TBL] [Abstract][Full Text] [Related]
12. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Abaji R; Krajinovic M
Pharmgenomics Pers Med; 2017; 10():143-156. PubMed ID: 28507448
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease.
Andoh A; Kawahara M; Imai T; Tatsumi G; Inatomi O; Kakuta Y
J Gastroenterol; 2021 Oct; 56(10):881-890. PubMed ID: 34287682
[TBL] [Abstract][Full Text] [Related]
15. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Roberts RL; Barclay ML
Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
[TBL] [Abstract][Full Text] [Related]
16. PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients.
Franca R; Stocco G; Favretto D; Giurici N; Del Rizzo I; Locatelli F; Vinti L; Biondi A; Colombini A; Fagioli F; Barisone E; Pelin M; Martellossi S; Ventura A; Decorti G; Rabusin M
Pharmacogenomics J; 2020 Jun; 20(3):415-425. PubMed ID: 31792371
[TBL] [Abstract][Full Text] [Related]
17. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.
Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L
Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571
[TBL] [Abstract][Full Text] [Related]
18. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
20. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
